Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

An anti-inflammatory peptide discovered by David Greaves and his group in the Dunn School of Pathology will be tested for its ability to treat psoriasis following a licensing deal between the University of Oxford’s ISIS Innovation and San Francisco start-up Rogne Biosciences.